BioHarvest Sciences Inc. files Form 6-K current reports as a foreign issuer, with exhibits that document company announcements and material changes. These filings cover the company's Botanical Synthesis platform, its VINIA-branded nutraceutical products, CDMO activities for plant-based compounds, earnings-call announcements, and business updates.
The filing record also includes governance and capital-structure subjects such as board composition changes, executive leadership transitions, long-term incentive awards, stock options, restricted share units, and equity incentive plan activity. Together, the disclosures provide formal records of BioHarvest's operating focus, public-company governance, compensation structure, and recurring communications to the market.
BioHarvest Sciences Inc. announced that its proprietary Olive Cell composition has reached commercial readiness and is available for licensing and commercialization through its CDMO business. The company says development, commercial-scale manufacturing readiness and the applicable self-affirmed U.S. GRAS process are complete. Its GMP facility is positioned to begin production in accordance with the requirements and timing of a future customer or partner.
In preliminary in-vitro models, Olive Cell reduced lipid accumulation by up to 37% in HepG2 liver cells and collagen type I accumulation by up to 50% in LX-2 cells; both effects were dose-dependent. The results have not been demonstrated in human studies. BioHarvest says the GRAS conclusion applies to intended uses, is not FDA approval and does not establish efficacy for a disease or medical condition.
BioHarvest Sciences Inc. (BHST) and Tate & Lyle PLC reported a milestone in their next-generation sweetener development programme: the programme demonstrated that BioHarvest’s Botanical Synthesis™ platform is capable of producing the targeted sweetening solution.
The companies said development activities continue to advance in line with expectations. The milestone builds on their expanded collaboration announced in May 2026. BioHarvest describes Botanical Synthesis as a way to develop and manufacture plant-based compositions without growing the underlying plant, and says its CDMO business partners with customers to develop, scale and manufacture those compositions.
BioHarvest Sciences Inc. authorized a normal course issuer bid to repurchase up to 1,133,392 common shares, equal to 5% of its outstanding common shares and the maximum percentage allowed under an NCIB in any 12-month period. The Board said it believes the market price may not fully reflect the Company’s underlying business value and future growth prospects.
Purchases will be made in the open market through Nasdaq at prevailing market prices, with management determining timing, quantity and price subject to applicable securities laws. All shares repurchased under the NCIB will be retired.
BIOHARVEST SCIENCES INC. (BHST) reported that its common shares have been registered for trading on the Tel Aviv Stock Exchange (TASE), creating a dual listing alongside its existing listing on the Nasdaq Capital Market. The company’s common shares began trading on the TASE on September 8, 2026.
Under the TASE registration, the company listed 22,667,842 outstanding common shares, up to 4,516,021 common shares reserved for its equity incentive plan (including options and restricted share units), and 610,742 common shares issuable upon exercise of investor warrants. The shares trade on TASE under the English symbol BHST and an alternative Hebrew symbol. The company states that all future EDGAR submissions will also be filed on the Israeli MAGNA Disclosure System.
BIOHARVEST SCIENCES INC. (BHST) reported the commercial launch of single-dose VINIA® Daily Chews, a new chewable format of its proprietary red-grape cell composition VINIA. The product extends VINIA beyond capsules and is intended to broaden the brand’s addressable market and daily usage occasions.
Each individually packaged Daily Chew delivers 400 mg of VINIA, matching the company’s capsule dosage, and includes 6 mg of piceid resveratrol, a daily amount described as clinically shown to increase arterial dilation and improve blood flow. Management states that early feedback on the chewable format indicates strong engagement and retention relative to internal expectations for a new delivery form.
BioHarvest highlights the launch as further evidence of its Botanical Synthesis platform and its strategy to operate both as a CDMO partner and as a developer of proprietary compositions. The company notes that VINIA’s format expansion provides a live example for potential CDMO customers of how plant-cell compositions can move from development through scaled manufacturing into differentiated consumer products.
BioHarvest Sciences Inc. (BHST) reported that Chief Executive Officer Zaki Rakib will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, held September 14-16, 2026. The in-person company presentation is scheduled for September 15, 2026, at 4:00 PM local time.
Rakib will also participate in one-on-one investor meetings during the conference. He highlighted recent “major advancements” in the company’s CDMO research and development programs, including securing its first manufacturing and supply agreement, and plans to discuss progress and opportunities related to BioHarvest’s botanical synthesis platform.
The presentation will be accessible via a publicly available live webcast, with in-person attendance requiring conference registration. BioHarvest describes itself as a leader in Botanical Synthesis, using a patented technology platform to grow plant-based compounds for CDMO projects and proprietary nutraceutical health and wellness products.
BioHarvest Sciences Inc. (BHST) plans to become dual-listed by offering its ordinary shares for trading on the Tel Aviv Stock Exchange in addition to the Nasdaq Capital Market. Trading on the TASE is expected to begin on September 8, 2026, subject to completion of the listing process.
The company has requested TASE registration of all securities eligible to trade there, including 22,667,842 outstanding common shares, up to 4,516,021 common shares tied to its Equity Incentive Plan, and 610,742 common shares issuable upon exercise of investor warrants. Any future issuance and listing of additional common shares will require TASE approval.
BioHarvest Sciences reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, with a 58% gross margin. Operating loss was $2.5 million and net loss was $3.7 million, or $0.17 per share. Adjusted EBITDA loss was $1.6 million.
The company secured its first CDMO manufacturing and supply agreement with a UAE-based fragrance customer, supporting an anticipated 20 tons of rare botanical fragrance production over two years, with initial limited production expected as early as the first half of 2027. Cash and cash equivalents plus bank deposits totaled $16.2 million as of June 30, 2026.
Guidance for 2026 was revised: CDMO revenue is now expected at $4–$5 million with EBITDA loss reduced to $1.5–$2.5 million, while VINIA D2C revenue is lowered to $33–$35 million and EBITDA is now forecast as a $1.5–$2.5 million loss as spending shifts to manufacturing capacity. Consolidated EBITDA loss is projected at $3–$5 million.
BioHarvest Sciences Inc. reported H1 2026 revenue of $17,344 thousand, up modestly year over year, with 94% from its Products Business Unit and the balance from CDMO Services. Gross margin was 58%, generating a net loss of $6,356 thousand (loss per share $0.28).
Cash and cash equivalents were $15,211 thousand and bank deposits $1,012 thousand as of June 30, 2026, supporting working capital of $14,504 thousand. Some high‑rate short-term loans and a convertible facility were fully repaid, while investor notes totaling $2,662 thousand remain outstanding.
The company flags substantial doubt about its ability to continue as a going concern due to ongoing losses and financing uncertainty, although management expects existing liquidity and operations to fund at least 12 months. Operations are organized into Products and CDMO Services business units; in H1 2026, Products revenue grew 4% and CDMO Services 43% versus the prior year.
BioHarvest Sciences Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, held August 11-13, 2026. Chief Executive Officer Zaki Rakib is scheduled to deliver a company presentation on Wednesday, August 12, 2026, at 1:00 p.m. and will also hold one-on-one investor meetings on August 11-12.
The presentation will be available via a publicly accessible live webcast for online pre-registrants, while in-person attendance requires conference registration. BioHarvest describes itself as a leader in Botanical Synthesis, operating both as a CDMO for plant-based compounds and as a developer of proprietary nutraceutical health and wellness products.